NexImmune, a start-up company formed in part by US-based Johns Hopkins University School of Medicine faculty members, has hired both a executive president and a chairman of its clinical and scientific advisory board as part of a technology transfer license for developing immunity against diseases and cancers. Kenneth Carter has joined NexImmune as its executive president and Jonathan Schneck has become chairman of the company’s Clinical and Scientific Advisory Board. Previously, Carter was also chief executive for 10 years at Avalon Pharmaceuticals until its merger with Clinical Data. Prior to Avalon, Carter directed the gene mapping initiative at Human Genome Sciences, which discovered, cloned, and chromosomal mapped dozens of novel human genes and he is also on the advisory council for the Center for Biotechnology Education at The Johns Hopkins University, where he also holds an adjunct faculty appointment. Schneck is a professor of pathology, oncology and medicine and director of the Human Immunology Program at the Institute for Cellular Engineering at John Hopkins. His and Mathias Oelke’s laboratory at Johns Hopkins University has also created the Artificial Immune (AIM) nanotechnology for immuno-therapy, which involves engineering artificial cells to stimulate specific immune responses (pictured). This work was awarded a $12m grant in 2009, the largest basic science immunology grant in the history of Johns Hopkins University. This AIM nanotechnology has just been licensed by Johns Hopkins Technology Transfer office to NexImmune. In related news, Carter is also now chairman of Noble Life Sciences, a provider of preclinical research services to the biotechnology and pharmaceutical industries set up by five healthcare entrepreneurs that were involved in NexImmune’s formation. He stepped up from president of Noble at the start of January to take his new role at NexImmune.
NexImmune protects with senior hires
Jan 15, 2012 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Beyond the Breakthrough: Jennifer Kuan
Silicon Valley remains unique, and small — even on the outskirts, a different reality hits. Jennifer Kuan tells us how that could be changed.
Age is just a number: 10 spinouts trying to cheat death
What if living to 100 was the norm rather than the exception for humans? Here are 10 companies using university research to make it happen.
Mar 14, 2024
Monterey, CA (USA)
May 9, 2024
May 22, 2024
Jun 26, 2024